Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Inventory (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Inventory for 7 consecutive years, with $5.4 million as the latest value for Q4 2025.

  • Quarterly Inventory fell 25.58% to $5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.4 million through Dec 2025, down 25.58% year-over-year, with the annual reading at $5.4 million for FY2025, 25.58% down from the prior year.
  • Inventory hit $5.4 million in Q4 2025 for Harmony Biosciences Holdings, down from $6.9 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $7.2 million in Q4 2024 to a low of $4.1 million in Q1 2023.
  • Historically, Inventory has averaged $5.5 million across 5 years, with a median of $5.3 million in 2021.
  • Biggest five-year swings in Inventory: soared 121.68% in 2021 and later decreased 25.58% in 2025.
  • Year by year, Inventory stood at $4.9 million in 2021, then grew by 0.72% to $4.9 million in 2022, then grew by 9.09% to $5.4 million in 2023, then soared by 34.22% to $7.2 million in 2024, then fell by 25.58% to $5.4 million in 2025.
  • Business Quant data shows Inventory for HRMY at $5.4 million in Q4 2025, $6.9 million in Q3 2025, and $6.3 million in Q2 2025.